ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.

Abstract

Pulmonary atypical carcinoid (AC) is an extremely rare neuroendocrine tumor. The neurotrophic tropomyosin receptor kinase (NTRK) fusions are reported in only 0.5% of nonsmall cell lung cancer, and are more rare in AC with only one previously reported case. Currently, there is little established evidence on the optimal therapeutic strategies and prognosis for advanced cases. We present a female patient with metastatic AC after complete resection. Due to low expression of somatostatin receptor in this case, somatostatin analogs and peptide receptor radionuclide therapy were not available. After pursuing other alternative treatments, including chemotherapy (ie, carboplatin, etoposide, capecitabine, temozolomide, and paclitaxel), everolimus, and atezolizumab, she returned with significant progression, including innumerable subcutaneous nodules, left pleura metastasis, multiple bone metastases, and brain metastases. New biopsy analysis revealed an ETV6-NTRK2 fusion. She was immediately administered the first-generation tropomyosin receptor kinase inhibitor entrectinib at a dose of 600 mg q.d. A subsequent month of treatment resulted in a complete response in all of the metastatic lung lesions. To date, she has maintained sustained benefit for at least 1 year from initiation of entrectinib. Here, we present the first case of a female patient with metastatic AC harboring the ETV6-NTRK2 fusion, and successfully treated with entrectinib, providing evidence for the application of entrectinib in patients with NTRK-positive AC, and underscoring the critical role of molecular profiling for such cases.

• Authors: Wusheng Zhang, Sen Tian, Xiang Li, Yilin Chen, Xinyu Wang, Yunshuo Zhang, Lihui Lv, Yonghua Li, Hui Shi, Chong Bai
• Journal: Clinical lung cancer (Clin Lung Cancer) Vol. 25 Issue 3 Pg. 215-224.e3 (May 2024) ISSN: 1938-0690 [Electronic] United States
• PMID: 38584068 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2024 Elsevier Inc. All rights reserved.

Chemical References

• entrectinib
• tropomyosin-related kinase-B, human

Topics

• Humans
• Female
• Carcinoid Tumor (drug therapy, pathology, genetics)
• Lung Neoplasms (drug therapy, pathology, genetics)
• Oncogene Proteins, Fusion (genetics)
• Indazoles (therapeutic use)
• Benzamides (therapeutic use)
• Middle Aged
• Receptor, trkB (genetics)
• Protein Kinase Inhibitors (therapeutic use)
• Membrane Glycoproteins